Gefurulimab - Alexion AstraZeneca Rare Disease
Alternative Names: ALXN-1720Latest Information Update: 06 Feb 2024
At a glance
- Originator Alexion AstraZeneca Rare Disease
- Class Recombinant fusion proteins
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myasthenia gravis
- Phase I Proteinuria
Most Recent Events
- 22 Nov 2023 Phase-I clinical trials in Myasthenia gravis (In adults, In the elderly, In volunteers) in Canada (SC) (NCT06208488)
- 31 May 2023 Alexion Pharmaceuticals completes a phase-I clinical trial in Proteinuria in South Korea (SC) (NCT05314231)
- 22 Apr 2023 Pharmacokinetics, immunogenicity and adverse events data from a phase I trial in Healthy volunteers presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)